A
Andrew J. Martin
Researcher at University of New South Wales
Publications - 897
Citations - 43053
Andrew J. Martin is an academic researcher from University of New South Wales. The author has contributed to research in topics: Medicine & Academic achievement. The author has an hindex of 84, co-authored 819 publications receiving 36203 citations. Previous affiliations of Andrew J. Martin include University of Western Australia & Max Planck Society.
Papers
More filters
Journal ArticleDOI
DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
Sean McBride,Tamim Niazi,Scott Williams,Ian D. Davis,Martin R. Stockler,Andrew J. Martin,Karen Bracken,Felicia Roncolato,L. Elise Horvath,S. Sengupta,Jarad Martin,Teesin Lim,Simon M. Hughes,Ray McDermott,James W.F. Catto,Paul Kelly,Wendy R. Parulekar,Scott C. Morgan,Ricardo A. Rendon,Christopher Sweeney +19 more
TL;DR: This study aims to determine the efficacy of adding darolutamide to ADT and RT in the setting of either primary definitive therapy, or salvage therapy for very high-risk PC, with secondary endpoints metastasis-free survival, PC-specific survival, PSA-progression free survival, and identification of prognostic and/or predictive biomarkers of treatment response, safety, and resistance to study treatment.
Journal ArticleDOI
Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer
Katrin Marie Sjoquist,Andrew J. Martin,Nick Pavlakis,David Goldstein,Eric Tsobanis,Daniel Moses,Richard Maher,Wendy Hague,Val Gebski,Martin R. Stockler,John Simes,The Royal Australasian College of Surgeons Snac Trial Group +11 more
TL;DR: In this paper , the authors assessed the value of central adjudication of investigator-assessed PFS times of participants in a double-blind, randomised phase 2 trial evaluating regorafenib versus placebo in advanced gastro-oesophageal cancer (AGITG INTEGRATE).